These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28223686)

  • 1. Metabolic profiling of presymptomatic Huntington's disease sheep reveals novel biomarkers.
    Skene DJ; Middleton B; Fraser CK; Pennings JL; Kuchel TR; Rudiger SR; Bawden CS; Morton AJ
    Sci Rep; 2017 Feb; 7():43030. PubMed ID: 28223686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolomic Analysis of Plasma in Huntington's Disease Transgenic Sheep (Ovis aries) Reveals Progressive Circadian Rhythm Dysregulation.
    Spick M; Hancox TPM; Chowdhury NR; Middleton B; Skene DJ; Morton AJ
    J Huntingtons Dis; 2023; 12(1):31-42. PubMed ID: 36617787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disturbances in plasma as biomarkers for Huntington's disease.
    Cheng ML; Chang KH; Wu YR; Chen CM
    J Nutr Biochem; 2016 May; 31():38-44. PubMed ID: 27133422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic disruption identified in the Huntington's disease transgenic sheep model.
    Handley RR; Reid SJ; Patassini S; Rudiger SR; Obolonkin V; McLaughlan CJ; Jacobsen JC; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RL; Snell RG
    Sci Rep; 2016 Feb; 6():20681. PubMed ID: 26864449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DI/LC-MS/MS-Based Metabolome Analysis of Plasma Reveals the Effects of Sequestering Agents on the Metabolic Status of Dairy Cows Challenged with Aflatoxin B
    Ogunade I; Jiang Y; Pech Cervantes A
    Toxins (Basel); 2019 Nov; 11(12):. PubMed ID: 31779109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): Compensatory neuroprotection in a neurodegenerative disease?
    Morton AJ; Middleton B; Rudiger S; Bawden CS; Kuchel TR; Skene DJ
    J Pineal Res; 2020 Mar; 68(2):e12624. PubMed ID: 31742766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted biochemical profiling of brain from Huntington's disease patients reveals novel metabolic pathways of interest.
    Graham SF; Pan X; Yilmaz A; Macias S; Robinson A; Mann D; Green BD
    Biochim Biophys Acta Mol Basis Dis; 2018 Jul; 1864(7):2430-2437. PubMed ID: 29684586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study.
    McGarry A; Gaughan J; Hackmyer C; Lovett J; Khadeer M; Shaikh H; Pradhan B; Ferraro TN; Wainer IW; Moaddel R
    Sci Rep; 2020 Nov; 10(1):20490. PubMed ID: 33235276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free carnitine and branched chain amino acids are not good biomarkers in Huntington's disease.
    Castilhos RM; Augustin MC; Santos JAD; Pedroso JL; Barsottini O; Saba R; Ferraz HB; Vargas FR; Furtado GV; Polese-Bonatto M; Rodrigues LP; Sena LS; Vargas CR; Saraiva-Pereira ML; Jardim LB; Neurogenética R
    Arq Neuropsiquiatr; 2020 Feb; 78(2):81-87. PubMed ID: 32159721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of elevated urea as a severe, ubiquitous metabolic defect in the brain of patients with Huntington's disease.
    Patassini S; Begley P; Reid SJ; Xu J; Church SJ; Curtis M; Dragunow M; Waldvogel HJ; Unwin RD; Snell RG; Faull RL; Cooper GJ
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):161-6. PubMed ID: 26522227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma biomarker discovery for early chronic kidney disease diagnosis based on chemometric approaches using LC-QTOF targeted metabolomics data.
    Benito S; Sánchez-Ortega A; Unceta N; Jansen JJ; Postma G; Andrade F; Aldámiz-Echevarria L; Buydens LMC; Goicolea MA; Barrio RJ
    J Pharm Biomed Anal; 2018 Feb; 149():46-56. PubMed ID: 29100030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Untargeted metabolic profiling identifies interactions between Huntington's disease and neuronal manganese status.
    Kumar KK; Goodwin CR; Uhouse MA; Bornhorst J; Schwerdtle T; Aschner M; McLean JA; Bowman AB
    Metallomics; 2015 Feb; 7(2):363-70. PubMed ID: 25599126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington's disease.
    Rodinova M; Krizova J; Stufkova H; Bohuslavova B; Askeland G; Dosoudilova Z; Juhas S; Juhasova J; Ellederova Z; Zeman J; Eide L; Motlik J; Hansikova H
    Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31278192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.
    Mochel F; Charles P; Seguin F; Barritault J; Coussieu C; Perin L; Le Bouc Y; Gervais C; Carcelain G; Vassault A; Feingold J; Rabier D; Durr A
    PLoS One; 2007 Jul; 2(7):e647. PubMed ID: 17653274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolomic Nuclear Magnetic Resonance Studies at Presymptomatic and Symptomatic Stages of Huntington's Disease on a
    Bertrand M; Decoville M; Meudal H; Birman S; Landon C
    J Proteome Res; 2020 Oct; 19(10):4034-4045. PubMed ID: 32880177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mass spectrometry-based method for simultaneous determination of asymmetric and symmetric dimethylarginine, l-arginine and l-citrulline optimized for LC-MS-TOF and LC-MS/MS.
    Wiśniewski J; Fleszar MG; Piechowicz J; Krzystek-Korpacka M; Chachaj A; Szuba A; Lorenc-Kukula K; Masłowski L; Witkiewicz W; Gamian A
    Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28436051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic profiling for the identification of Huntington biomarkers by on-line solid-phase extraction capillary electrophoresis mass spectrometry combined with advanced data analysis tools.
    Pont L; Benavente F; Jaumot J; Tauler R; Alberch J; Ginés S; Barbosa J; Sanz-Nebot V
    Electrophoresis; 2016 Mar; 37(5-6):795-808. PubMed ID: 26685060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (1)H NMR based metabolomics of CSF and blood serum: a metabolic profile for a transgenic rat model of Huntington disease.
    Verwaest KA; Vu TN; Laukens K; Clemens LE; Nguyen HP; Van Gasse B; Martins JC; Van Der Linden A; Dommisse R
    Biochim Biophys Acta; 2011 Nov; 1812(11):1371-9. PubMed ID: 21867751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.